# OnCo record recurrent-metastatic-nasopharyngeal-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "recurrent-metastatic-nasopharyngeal-carcinoma" ;
  schema:name "Recurrent and metastatic nasopharyngeal carcinoma"@en ;
  schema:alternateName "R/M NPC"@en, "Metastatic nasopharyngeal carcinoma"@en, "Locally recurrent nasopharyngeal carcinoma"@en, "Stage IVB nasopharyngeal carcinoma"@en ;
  schema:description "Recurrent or metastatic nasopharyngeal carcinoma is nasopharyngeal cancer that has come back after radiotherapy or spread to the bones, liver or lungs. Gemcitabine with cisplatin is the chemotherapy backbone, adding a PD-1 antibody such as toripalimab in JUPITER-02 and later trials lengthened survival and became standard, and local recurrence is treated with endoscopic surgery or re-irradiation."@en ;
  schema:url <https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nasopharyngeal_carcinoma> ;
  schema:citation <https://doi.org/10.1001/jama.2023.20181>, <https://doi.org/10.1200/JCO.20.03237>, <https://en.wikipedia.org/wiki/Nasopharyngeal_carcinoma> ;
  onco:tag "subtype-page", "head-and-neck" ;
  onco:related <https://onco.cc/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/>, <https://onco.cc/cancers/nasopharyngeal/>, <https://onco.cc/cancers/recurrent-metastatic-hnscc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/tors/>, <https://onco.cc/technologies/tcr-t/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/penpulimab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:terms <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/terms/re-irradiation/>, <https://onco.cc/terms/ebv-term/>, <https://onco.cc/terms/ctdna/> ;
  onco:trials <https://onco.cc/trials/jupiter-02/>, <https://onco.cc/trials/captain-1st/>, <https://onco.cc/trials/nct04974398/>, <https://onco.cc/trials/taishan-301/>, <https://onco.cc/trials/nct05294172/>, <https://onco.cc/trials/nct06118333/>, <https://onco.cc/trials/nct06976190/>, <https://onco.cc/trials/nct05126719/>, <https://onco.cc/trials/nct06839066/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021/>, <https://onco.cc/key-papers/paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016/>, <https://onco.cc/key-papers/paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021/> ;
  onco:pipeline <https://onco.cc/trials/taishan-301/>, <https://onco.cc/trials/nct05294172/>, <https://onco.cc/trials/nct06118333/>, <https://onco.cc/trials/nct06976190/>, <https://onco.cc/trials/nct05126719/>, <https://onco.cc/trials/nct06839066/>, <https://onco.cc/drugs/yl201/>, <https://onco.cc/drugs/kl-a167/>, <https://onco.cc/drugs/mrg003/>, <https://onco.cc/drugs/hmbd-001/>, <https://onco.cc/technologies/tcr-t/> ;
  onco:standardOfCare <https://onco.cc/technologies/tors/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/terms/re-irradiation/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/trials/jupiter-02/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/trials/captain-1st/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/penpulimab/>, <https://onco.cc/trials/nct04974398/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/trials/taishan-301/>, <https://onco.cc/trials/nct05294172/>, <https://onco.cc/trials/nct06118333/>, <https://onco.cc/trials/nct06976190/>, <https://onco.cc/trials/nct05126719/>, <https://onco.cc/trials/nct06839066/>, <https://onco.cc/technologies/tcr-t/>, <https://onco.cc/technologies/sbrt/> .